Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$21.60
Change (%) Stock is Up 0.70 (3.35%)
Volume414,432
Data as of 12/09/16 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $21.60 with a 52 week high of $24.55 and a 52 week low of $7.07.
Recent NewsMore >>
DateTitle 
11/29/16REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform (NAV), and Voyager Therapeutics, Inc. (Nasdaq:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announce... 
Printer Friendly Version
11/17/16REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated (AAV) gene therapy based on its proprietary NAV® Technology Platform (NAV), today announced that President and CEO Kenneth T. Mills will present as part of the Gene Therapy Panel at the 28th Annual Piper Jaffray Healthcare Conference. The panel will take place on Wednesday, November 30, 2016 a... 
Printer Friendly Version
11/09/16REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
On track to dose first patient for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia by the end of 2016 Initiated manufacturing of material for Phase I clinical trial of RGX-314 for the treatment of wet age-related macular degeneration; IND filing planned for early 2017 Anticipate completion of new, advanced manufacturing and analytics lab by the end of 2016 $184.9 million in cash, cash equivalents and marketable securities as... 
Printer Friendly Version
11/02/16REGENXBIO to Host Conference Call on November 9 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 9, 2016 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2016 and recent operational highlights. To acce... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
11/09/16
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.